Qualifying for Semaglutide: What You Really Need to Know

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

"Do I qualify for semaglutide" has no single answer, because semaglutide is sold under several FDA-approved labels with different indications, and each label defines a different population. Semaglutide injection marketed as Ozempic is a type 2 diabetes product with no BMI criterion anywhere in its labeling. Semaglutide tablets marketed as Rybelsus and as Ozempic tablets are also type 2 diabetes products. Wegovy — injection and tablets — carries the weight-management, cardiovascular and liver indications. Qualifying means matching your clinical picture to one of those labels, and then clearing the contraindications.

Four Labels, Four Different Pictures

Ozempic injection is indicated to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Weight management is not among them.

The oral semaglutide products sit in the same diabetes lane: the current labeling covers Rybelsus at 3, 7 and 14 mg and Ozempic tablets at 1.5, 4 and 9 mg, for type 2 diabetes and for cardiovascular risk reduction. Wegovy is the outlier, and it is the label most people mean when they ask about qualifying for weight loss.

What Wegovy's Label Actually Requires

Wegovy injection is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries an indication to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and an accelerated-approval indication for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis.

Wegovy tablets — 1.5, 4, 9 and 25 mg, with a 25 mg maintenance dosage — carry only the first two of those. They do not carry the pediatric indication or the MASH indication. The adult weight-management trials enrolled participants with a BMI of 30 kg/m² or greater, or 27 to 29.9 kg/m² with at least one weight-related comorbid condition, which is where the familiar numbers come from.

The label also states an explicit limitation of use: concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. Being on another agent in this class is a genuine disqualifier for combining them.

The Contraindications That End the Conversation

Two rule people out absolutely. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 — the basis of the boxed warning, which reflects dose-dependent and treatment-duration-dependent thyroid C-cell tumors observed in rodents at clinically relevant exposures, with human relevance undetermined. It is also contraindicated after a prior serious hypersensitivity reaction to semaglutide or any excipient, including anaphylaxis and angioedema.

These are questions about your family, not just about you. A parent or sibling with medullary thyroid carcinoma is disqualifying information, which is why any legitimate intake asks about family history rather than only personal history.

The Warnings That Shape the Conversation

Beyond the absolute contraindications, the Wegovy label carries a list that turns qualification into a discussion rather than a checkbox: acute pancreatitis; acute gallbladder disease, with the note that substantial or rapid weight loss itself increases the risk of cholelithiasis; hypoglycemia when used with insulin or an insulin secretagogue; acute kidney injury due to volume depletion; severe gastrointestinal adverse reactions, reported in 4.1% of Wegovy injection patients versus 0.9% on placebo, with the product not recommended in severe gastroparesis; diabetic retinopathy complications in type 2 diabetes; increases in resting heart rate; and rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation.

Reproductive considerations sit alongside these. The label states semaglutide may cause fetal harm, directs discontinuation when pregnancy is recognized for patients treated for cardiovascular risk reduction or weight reduction, and advises discontinuation at least two months before a planned pregnancy because of semaglutide's long half-life. Breastfeeding is not recommended during treatment with Wegovy tablets.

BMI Is a Threshold, Not a Verdict

Body mass index earned its role in these labels because it was the enrollment criterion in the trials, not because it is a precise measure of health. It does not distinguish muscle from fat, and it performs differently across body compositions and ancestries. A prescriber weighing eligibility is looking at the whole picture — blood pressure, lipids, glycemic markers, sleep apnea, joint disease, cardiovascular history, medication list, previous attempts and what happened to them.

That is also why an online BMI calculator that returns "you qualify" is not a clinical determination. Meeting a trial's enrollment threshold and being an appropriate candidate for treatment are related but not identical questions.

What Compounded Access Does and Does Not Change

Compounded semaglutide is prepared by a licensed pharmacy against a prescription for an individual patient. The FDA states plainly that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing. There is no approved generic semaglutide, so no compounded preparation is a generic version of any brand.

What compounded access removes is the insurance adjudication layer. It does not loosen the clinical screening — the same contraindications, the same warnings and the same need for follow-up apply, because the risk profile belongs to the molecule rather than to the payment method. PlexusDx dispenses exclusively through licensed 503A compounding pharmacies against patient-specific prescriptions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What BMI do you need to qualify for semaglutide?

It depends on the product. Ozempic has no BMI criterion at all, because it is indicated for type 2 diabetes rather than weight management. Wegovy's weight-reduction indication covers adults with obesity, and adults with overweight plus at least one weight-related comorbid condition; the supporting adult trials enrolled participants with a BMI of 30 kg/m² or greater, or 27 to 29.9 kg/m² with at least one weight-related condition.

Who is absolutely disqualified from taking semaglutide?

The labels contraindicate use in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a prior serious hypersensitivity reaction to semaglutide or any excipient in the product, including anaphylaxis or angioedema. Family history matters here as much as personal history, which is why a proper intake asks about relatives, not only about you.

Can I take semaglutide alongside another GLP-1 medication?

The Wegovy label states a limitation of use: concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. If you are already taking a medication in this class, tell your prescriber before any new prescription is written. Combining agents in this class is not a strategy the labeling supports.

Does having type 2 diabetes change eligibility?

It changes which product fits and what needs monitoring. Type 2 diabetes opens the Ozempic and oral semaglutide indications, and Wegovy's label directs blood glucose monitoring before and during treatment in patients with diabetes. It also raises specific concerns: increased hypoglycemia risk when combined with insulin or an insulin secretagogue, and the diabetic retinopathy warning, which calls for monitoring in patients with a history of retinopathy.

Is qualifying easier through a compounded provider?

The clinical screening should be the same. Compounded semaglutide requires a prescription written for a specific patient by a licensed prescriber, and the contraindications and warnings belong to the molecule rather than to the payment pathway. What cash-pay access removes is insurance prior authorization and formulary restriction. The FDA also notes compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.